Journal: CNS Neuroscience & Therapeutics

Article Title: ATF3 Promotes Solasonine‐Triggered Ferroptosis in Glioma Cells by Suppressing Glycolysis

doi: 10.1002/cns.71226

Figure Lengend Snippet: (A) Glioma cell survival at 24 h after SS treatment. (B) Glioma cell survival after pretreatment with DFO, FAC, Fer‐1, and Lip‐1, respectively, for 1 h before SS treatment. (C–F) Intracellular ROS, MDA, GSH/GSSG, and ferrous ion levels at 6, 12, and 24 h after SS treatment, with and without DFO, Fer‐1, Lip‐1, and FAC pretreatment for 1 h before SS treatment, respectively. (G) Glioma cell survival after SS treatment, with and without pretreatment with NAC and GSH for 1 h before SS treatment, respectively. (H) Western blots of ferroptosis‐related protein expression after SS treatment. Cell survival was assessed by the CCK‐8 assay. (I) Western blots of ATF3 expression in the cytoplasm and nuclei of SS‐treated cells. (J) Viability of cells treated with siATF3 followed by SS. (K–N) Ferrous ion, MDA, GSH/GSSG, and ROS levels in cells treated with siATF3 followed by SS. (O) Confocal microscopic images of ATF3 immunofluorescence in U251 cells treated with SS. (P, Q) Confocal microscopy images and fluorescence intensity measurements of mitochondrial superoxide in SS‐ and siATF3‐treated U251 and T98 cells. * p < 0.01 versus control, # p < 0.01 versus treatment group.

Article Snippet: Transferrin receptor (TfR), transferrin, ferroportin (FPN), ferritin, GPX4, xCT, H2A, ß‐actin, ATG5, NCOA4, ferritin heavy chain (FTH), microtubule‐associated protein 1 light chain 3ß (LC3B), p62, pyruvate kinase M2 (PKM2), phosphofructokinase platelet type (PFKP), catalase, glucose‐regulated protein 78 (GRP78), protein kinase RNA–like endoplasmic reticulum kinase (PERK), ATF4, ATF3, and hexokinase 2 (HK2) antibodies were purchased from Abclonal (China).

Techniques: Western Blot, Expressing, CCK-8 Assay, Confocal, Immunofluorescence, Microscopy, Fluorescence, Control

Journal: CNS Neuroscience & Therapeutics

Article Title: ATF3 Promotes Solasonine‐Triggered Ferroptosis in Glioma Cells by Suppressing Glycolysis

doi: 10.1002/cns.71226

Figure Lengend Snippet: (A) Western blots of ferritinophagy‐related protein expression in glioma cells after SS treatment. (B–E) Cell viability and ROS, MDA, and ferrous ion levels after pretreatment with 3MA and Baf‐A1 followed by SS treatment. (F) Western blots of ferroptosis‐ and ferritinophagy‐related protein expression in glioma cells after 3MA and Baf‐A1 pretreatment and SS treatment. (G) Viability of glioma cells treated with siATG5 followed by SS. (H–J) ROS, MDA, and ferrous ion levels in glioma cells treated with siATG5 followed by SS. (K, L) Western blots of ferritinophagy‐ and ferroptosis‐related protein expression in glioma cells treated with siATG5 and siATF3, respectively, followed by SS. * p < 0.01 versus control, # p < 0.01 versus treatment group.

Article Snippet: Transferrin receptor (TfR), transferrin, ferroportin (FPN), ferritin, GPX4, xCT, H2A, ß‐actin, ATG5, NCOA4, ferritin heavy chain (FTH), microtubule‐associated protein 1 light chain 3ß (LC3B), p62, pyruvate kinase M2 (PKM2), phosphofructokinase platelet type (PFKP), catalase, glucose‐regulated protein 78 (GRP78), protein kinase RNA–like endoplasmic reticulum kinase (PERK), ATF4, ATF3, and hexokinase 2 (HK2) antibodies were purchased from Abclonal (China).

Techniques: Western Blot, Expressing, Control

Journal: CNS Neuroscience & Therapeutics

Article Title: ATF3 Promotes Solasonine‐Triggered Ferroptosis in Glioma Cells by Suppressing Glycolysis

doi: 10.1002/cns.71226

Figure Lengend Snippet: (A) Western blots of antioxidant‐related protein expression after SS treatment. (B, C) The intracellular hydrogen peroxide level and antioxidant‐related protein expression after pretreatment with SP and ATP, respectively, followed by SS treatment. (D) Ferrous ion levels after hydrogen peroxide treatment. (E, F) Western blots of ferritinophagy‐related protein expression in hydrogen peroxide– and NAC‐treated cells. (G–I) ATP, PA, and hydrogen peroxide levels in glioma cells treated with siATF3 and SS. (J) Western blots of glycolysis‐related protein expression in glioma cells treated with siATF3 and SS. * p < 0.01 versus control, # p < 0.01 versus treatment group.

Article Snippet: Transferrin receptor (TfR), transferrin, ferroportin (FPN), ferritin, GPX4, xCT, H2A, ß‐actin, ATG5, NCOA4, ferritin heavy chain (FTH), microtubule‐associated protein 1 light chain 3ß (LC3B), p62, pyruvate kinase M2 (PKM2), phosphofructokinase platelet type (PFKP), catalase, glucose‐regulated protein 78 (GRP78), protein kinase RNA–like endoplasmic reticulum kinase (PERK), ATF4, ATF3, and hexokinase 2 (HK2) antibodies were purchased from Abclonal (China).

Techniques: Western Blot, Expressing, Control

Journal: CNS Neuroscience & Therapeutics

Article Title: ATF3 Promotes Solasonine‐Triggered Ferroptosis in Glioma Cells by Suppressing Glycolysis

doi: 10.1002/cns.71226

Figure Lengend Snippet: (A–C) Western blots of ER stress–related protein expression after SS treatment with and without SP and ATP pretreatment, and after hydrogen peroxide treatment. (D–F) ROS, MDA, and ferrous ion levels in cells treated with SS after pretreatment with 4‐PBA. (G, H) Western blots of ferroptosis‐ and ER stress–related protein expression in cells treated with 4‐PBA and SS. * p < 0.01 versus control, # p < 0.01 versus treatment group.

Article Snippet: Transferrin receptor (TfR), transferrin, ferroportin (FPN), ferritin, GPX4, xCT, H2A, ß‐actin, ATG5, NCOA4, ferritin heavy chain (FTH), microtubule‐associated protein 1 light chain 3ß (LC3B), p62, pyruvate kinase M2 (PKM2), phosphofructokinase platelet type (PFKP), catalase, glucose‐regulated protein 78 (GRP78), protein kinase RNA–like endoplasmic reticulum kinase (PERK), ATF4, ATF3, and hexokinase 2 (HK2) antibodies were purchased from Abclonal (China).

Techniques: Western Blot, Expressing, Control

Journal: CNS Neuroscience & Therapeutics

Article Title: ATF3 Promotes Solasonine‐Triggered Ferroptosis in Glioma Cells by Suppressing Glycolysis

doi: 10.1002/cns.71226

Figure Lengend Snippet: (A) Photograph of nude mouse tumors. (B) Tumor volume over time. (C–F) Hydrogen peroxide, MDA, ferrous ion, and GSH/GSSG levels in tumor tissues from nude mice treated with high and low doses of SS. (G) Western blots of glycolysis‐, ferritinophagy‐, and ferroptosis‐related protein expression in tumor tissues. (H) H&E staining of intracranial orthotopic tumor following SS treatment. (I) Expression of intratumoral NCOA4, PKM2, and GPX4 in each treatment group (bar = 50 μm). * p < 0.01 versus control.

Article Snippet: Transferrin receptor (TfR), transferrin, ferroportin (FPN), ferritin, GPX4, xCT, H2A, ß‐actin, ATG5, NCOA4, ferritin heavy chain (FTH), microtubule‐associated protein 1 light chain 3ß (LC3B), p62, pyruvate kinase M2 (PKM2), phosphofructokinase platelet type (PFKP), catalase, glucose‐regulated protein 78 (GRP78), protein kinase RNA–like endoplasmic reticulum kinase (PERK), ATF4, ATF3, and hexokinase 2 (HK2) antibodies were purchased from Abclonal (China).

Techniques: Western Blot, Expressing, Staining, Control

Journal: Materials Today Bio

Article Title: EMSCs-derived exosomes rescue p75NTR −/− -mediated osteogenesis deficiency via PI3K/Akt/ERK1/2 signaling pathways

doi: 10.1016/j.mtbio.2026.103755

Figure Lengend Snippet: Schematic illustration of the fabrication and application of the WT-Exo–loaded coaxial nanofibrous membrane for rescuing p75NTR deficiency–associated osteogenic impairment and promoting bone regeneration.

Article Snippet: Osteogenesis-related antibodies, including anti-Col-I (A5786), anti-OPN (A1499), anti-activating transcription factor 4 (ATF4, A18687) and anti-ALP (A0514), were obtained from Abclonal Technology Co., Ltd. (Wuhan, China).

Techniques: Membrane

Journal: Materials Today Bio

Article Title: EMSCs-derived exosomes rescue p75NTR −/− -mediated osteogenesis deficiency via PI3K/Akt/ERK1/2 signaling pathways

doi: 10.1016/j.mtbio.2026.103755

Figure Lengend Snippet: Gene expression profiles between (SF/PCL 2:5 /PVA) WT-Exo and SF/PCL 2:5 /PVA groups. (A) Volcano plot displaying differentially expressed genes between the (SF/PCL 2:5 /PVA) WT-Exo and SF/PCL 2:5 /PVA groups. Red dots represent upregulated genes, and blue dots represent downregulated genes. (B) Heatmap of selected differentially expressed genes. (C) KEGG pathway enrichment analysis. (D) Gene Ontology (GO) analysis showing enriched biological processes, cellular components and molecular functions. (E) Venn diagram showing the overlap of differentially expressed genes annotated to the PI3K/Akt signaling pathway, ERK1/2 signaling cascade, and osteoblast differentiation–related gene sets. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: Osteogenesis-related antibodies, including anti-Col-I (A5786), anti-OPN (A1499), anti-activating transcription factor 4 (ATF4, A18687) and anti-ALP (A0514), were obtained from Abclonal Technology Co., Ltd. (Wuhan, China).

Techniques: Gene Expression, Analysis, Significance Assay

Journal: Materials Today Bio

Article Title: EMSCs-derived exosomes rescue p75NTR −/− -mediated osteogenesis deficiency via PI3K/Akt/ERK1/2 signaling pathways

doi: 10.1016/j.mtbio.2026.103755

Figure Lengend Snippet:

Article Snippet: Osteogenesis-related antibodies, including anti-Col-I (A5786), anti-OPN (A1499), anti-activating transcription factor 4 (ATF4, A18687) and anti-ALP (A0514), were obtained from Abclonal Technology Co., Ltd. (Wuhan, China).

Techniques: